Partnering with scientists to accelerate transformation in cancer research

Our Mission


The Mark Foundation for Cancer Research actively partners with scientists to accelerate research that will transform the prevention, diagnosis, and treatment of cancer. We fulfill our mission by supporting groundbreaking science carried out by individual investigators, multi-disciplinary teams, and early-stage companies in the United States and across the globe. Recognizing the obstacles that prevent scientific advances from improving patient outcomes, we maintain a nimble, high-impact approach to funding basic and translational cancer research that bridges the gap between bench and bedside through grants and venture investments.

latest news


Becky Bish Named Head of Discovery and Preclinical Research

Read More

Success Spotlight: Michelle Krogsgaard

Read More

The Mark Foundation and AACR Announce Five Grants to Support the “Science of the Patient”

Read More

Ryan Schoenfeld Named Chief Scientific Officer

Read More
View all news

Our Grant Portfolio


146 Grants

Over $121 Million Awarded


  • 47% Translational Science
  • 18% Technology Innovation
  • 23% Basic Research
  • 10% Therapeutic Discovery
  • 2% Clinical

Funding By Cancer Type


  • 50% All cancer types
  • 10% Others
  • 6% Leukemia
  • 4% Brain Tumors
  • 2% Melanoma
  • 12% Breast Cancer
  • 4% Pancreatic Cancer
  • 1% Colorectal Cancer
  • 8% Lung Cancer
  • 1% Lymphoma
  • 1% Ovarian Cancer
  • 1% Prostate Cancer

Over 60 Institutions

In 6 Countries


  • CANADA
  • NETHERLANDS
  • DENMARK
  • UNITED KINGDOM
  • FRANCE
  • USA